Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SonoSite snaps up Visualsonics

This article was originally published in The Gray Sheet

Executive Summary

Maker of hand-carried ultrasound systems is looking to adapt Visualsonics' "micro-ultrasound" technology for clinical applications after acquiring the firm for $71 million on May 27. Privately held Visualsonics makes ultra high-frequency micro-ultrasound devices for the pre-clinical research market, including the visualization of superficial anatomy on small living animals with microscopic detail, SonoSite explains. The technology can discern features as small as 40 microns versus 200 microns for conventional ultrasound, and it "has the potential to pave the way for a new era of extreme high-resolution ultrasound imaging of superficial anatomy in clinical medicine," the company says. Toronto-based Visualsonics had $30 million in sales over the past 12 months

You may also be interested in...



Former Sandoz Executive Kellum Admits US Price-Fixing

Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

Topics

UsernamePublicRestriction

Register

MT028951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel